American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationCancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationHarvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationBeatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72384-7 · Cited by 1,608
Cited by
Items 101–176 of 176
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S. M., & Coleman, W. B. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 327
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Bardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.002 · Cited by 326
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Zhou, L., Wang, R., Yao, C., Li, X., Wang, C., Zhang, X., Xu, C., Zeng, A., Zhao, D., & Zhang, F. (2015) · Nature Communications · doi:10.1038/ncomms7938 · Cited by 321
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Mosele, F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M.-P., Lacroix, L., Enrico, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.006 · Cited by 314
Emens, L. A., Molinero, L., Loi, S., Rugo, H. S., Schneeweiss, A., Diéras, V., Iwata, H., Barrios, C. H., Nechaeva, M., Nguyen-Duc, A., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab004 · Cited by 304
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast
Lester, S. C., Bose, S., Chen, Y.-Y., Connolly, J. L., de Baca, M. E., Fitzgibbons, P. L., Hayes, D. F., Kleer, C., O'Malley, F. P., Page, D. L., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.10.1515 · Cited by 302
Self-citationChia, S. K., Bramwell, V. H., Tu, D., Shepherd, L. E., Jiang, S., Vickery, T., Mardis, E., Leung, S., Ung, K., Pritchard, K. I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0286 · Cited by 302
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., Kim, I. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.251 · Cited by 300
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 298
Robertson, S., Azizpour, H., Smith, K., & Hartman, J. (2018) · Translational Research · doi:10.1016/j.trsl.2017.10.010 · Cited by 295
Practical implications of gene-expression-based assays for breast oncologists
Prat, A., Ellis, M. J., & Perou, C. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.178 · Cited by 295
Guiu, S., Michiels, S., André, F., Cortes, J., Denkert, C., Di Leo, A., Hennessy, B. T., Sorlie, T., Sotiriou, C., Turner, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds586 · Cited by 290
Self-citationIwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2574 · Cited by 288
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
Turner, N. C., Im, S.-A., Saura, C., Juric, D., Loibl, S., Kalinsky, K., Schmid, P., Loi, S., Sunpaweravong, P., Musolino, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404625 · Cited by 288
Incidence of Breast Cancer in the United States: Current and Future Trends
Anderson, W. F., Katki, H. A., & Rosenberg, P. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr257 · Cited by 285
Park, S., Koo, J. S., Kim, M. S., Park, H. S., Lee, J. S., Lee, J. S., Kim, S. I., & Park, B.-W. (2012) · The Breast · doi:10.1016/j.breast.2011.07.008 · Cited by 284
Fitzgibbons, P. L., Bradley, L. A., Fatheree, L. A., Alsabeh, R., Fulton, R. S., Goldsmith, J. D., Haas, T. S., Karabakhtsian, R. G., Loykasek, P. A., Marolt, M. J., et al. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0610-cp · Cited by 280
Self-citationMolecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Johnson, K. S., Conant, E. F., & Soo, M. S. (2021) · Journal of Breast Imaging · doi:10.1093/jbi/wbaa110 · Cited by 280
Occurrence of breast cancer subtypes in adolescent and young adult women
Keegan, T. H., DeRouen, M. C., Press, D. J., Kurian, A. W., & Clarke, C. A. (2012) · Breast Cancer Research · doi:10.1186/bcr3156 · Cited by 279
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Self-citationPatient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S. D., Alferez, D. G., Aparicio, S., Behbod, F., Bentires-Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 267
How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M., & Sherman, M. E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju165 · Cited by 265
Long term side effects of adjuvant chemotherapy in patients with early breast cancer
Tao, J. J., Visvanathan, K., & Wolff, A. C. (2015) · The Breast · doi:10.1016/j.breast.2015.07.035 · Cited by 258
Self-citationEngel, K. B., & Moore, H. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0702-rair.1 · Cited by 257
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
Updated UK Recommendations for HER2 assessment in breast cancer
Rakha, E. A., Pinder, S. E., Bartlett, J. M. S., Ibrahim, M., Starczynski, J., Carder, P. J., Provenzano, E., Hanby, A., Hales, S., Lee, A. H. S., et al. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202571 · Cited by 255
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Self-citationBartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0331-cp · Cited by 254
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
Gandhi, N., & Das, G. (2019) · Cells · doi:10.3390/cells8020089 · Cited by 227
Receptor conversion in distant breast cancer metastases
Hoefnagel, L. D., van de Vijver, M. J., van Slooten, H.-J., Wesseling, P., Wesseling, J., Westenend, P. J., Bart, J., Seldenrijk, C. A., Nagtegaal, I. D., Oudejans, J., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2645 · Cited by 226
Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
Hartman, A., Kaldate, R. R., Sailer, L. M., Painter, L., Grier, C. E., Endsley, R. R., Griffin, M., Hamilton, S. A., Frye, C. A., Silberman, M. A., et al. (2012) · Cancer · doi:10.1002/cncr.26576 · Cited by 220
Ki67 assessment in breast cancer: an update
Penault-Llorca, F., & Radosevic-Robin, N. (2017) · Pathology · doi:10.1016/j.pathol.2016.11.006 · Cited by 216
Bridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4845 · Cited by 214
Estrogen and Progesterone Receptors in Breast Cancer
Yip, C.-H., & Rhodes, A. (2014) · Future Oncology · doi:10.2217/fon.14.110 · Cited by 208
Self-citationPareja, F., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 206
CD74 and intratumoral immune response in breast cancer
Wang, Z.-Q., Milne, K., Webb, J. R., & Watson, P. H. (2017) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
Masucci, G. V., Cesano, A., Hawtin, R., Janetzki, S., Zhang, J., Kirsch, I., Dobbin, K. K., Alvarez, J., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 202
Plasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016) · Medicine · doi:10.1097/md.0000000000004614 · Cited by 201
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Cheang, M. C. U., Martin, M., Nielsen, T. O., Prat, A., Voduc, D., Rodriguez-Lescure, A., Ruiz, A., Chia, S., Shepherd, L., Ruiz-Borrego, M., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0372 · Cited by 194
Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., Stella, P. J., Burnette, B., Telli, M., Makower, D. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9331 · Cited by 189
Self-citationBiomarkers for the clinical management of breast cancer: International perspective
Patani, N., Martin, L., & Dowsett, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.27997 · Cited by 189
Self-citationMetzger Filho, O., Giobbie-Hurder, A., Mallon, E., Gusterson, B., Viale, G., Winer, E. P., Thürlimann, B., Gelber, R. D., Colleoni, M., Ejlertsen, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8133 · Cited by 188
Self-citationDigital image analysis outperforms manual biomarker assessment in breast cancer
Stålhammar, G., Fuentes Martinez, N., Lippert, M., Tobin, N. P., Mølholm, I., Kis, L., Rosin, G., Rantalainen, M., Pedersen, L., Bergh, J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.34 · Cited by 186
Castelló, A., Pollán, M., Buijsse, B., Ruiz, A., Casas, A. M., Baena-Cañada, J. M., Lope, V, Antolín, S., Ramos, M., Muñoz, M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.434 · Cited by 182
Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer
Chang, J. M., Park, I. A., Lee, S. H., Kim, W. H., Bae, M. S., Koo, H. R., Yi, A., Kim, S. J., Cho, N., & Moon, W. K. (2013) · European Radiology · doi:10.1007/s00330-013-2866-2 · Cited by 182
“A cut-off value of 1 % was used to define ER and PR positivity [25].”
MethodHuang, Y., Zhu, T., Zhang, X., Li, W., Zheng, X., Cheng, M., Ji, F., Zhang, L., Yang, C., Wu, Z., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101899 · Cited by 175
New concepts in the diagnosis and management of choroidal metastases
Mathis, T., Jardel, P., Loria, O., Delaunay, B., Nguyen, A.-M., Lanza, F., Mosci, C., Caujolle, J.-P., Kodjikian, L., & Thariat, J. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.09.003 · Cited by 172
Wetterskog, D., Lopez‐Garcia, M. A., Lambros, M. B., A'Hern, R., Geyer, F. C., Milanezi, F., Cabral, M. C., Natrajan, R., Gauthier, A., Shiu, K., et al. (2012) · The Journal of Pathology · doi:10.1002/path.2974 · Cited by 169
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Chen, L., Yang, L., Yao, L., Kuang, X.-Y., Zuo, W.-J., Li, S., Qiao, F., Liu, Y.-R., Cao, Z.-G., Zhou, S.-L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03867-9 · Cited by 169
Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer
Jeong, H., Hwang, I., Kang, S. H., Shin, H. C., & Kwon, S. Y. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e5 · Cited by 169
Na, D. G., Baek, J. H., Jung, S. L., Kim, J.-H., Sung, J. Y., Kim, K. S., Lee, J. H., Shin, J. H., Choi, Y. J., Ha, E. J., et al. (2017) · Korean Journal of Radiology · doi:10.3348/kjr.2017.18.1.217 · Cited by 168
Biomarker validation and testing
Hayes, D. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.004 · Cited by 167
Self-citationMale Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis
Liu, N., Johnson, K. J., & Ma, C. X. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.06.013 · Cited by 161
Guenther, S., Muirhead, L. J., Speller, A. V. M., Golf, O., Strittmatter, N., Ramakrishnan, R., Goldin, R. D., Jones, E., Veselkov, K., Nicholson, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2258 · Cited by 159
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2588-8 · Cited by 149
An approach for normalization and quality control for NanoString RNA expression data
Bhattacharya, A., Hamilton, A. M., Furberg, H., Pietzak, E., Purdue, M. P., Troester, M. A., Hoadley, K. A., & Love, M. I. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa163 · Cited by 122
Kim, J.-Y., Jeong, H. S., Chung, T., Kim, M., Lee, J. H., Jung, W. H., & Koo, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.17775 · Cited by 115
Wang, Y. “., Reder, N. P., Kang, S., Glaser, A. K., Yang, Q., Wall, M. A., Javid, S. H., Dintzis, S. M., & Liu, J. T. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0709 · Cited by 104
Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images
Rawat, R. R., Ortega, I., Roy, P., Sha, F., Shibata, D., Ruderman, D., & Agus, D. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-64156-4 · Cited by 100
Chen, T., Zhang, N., Moran, M. S., Su, P., Haffty, B. G., & Yang, Q. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.06.005 · Cited by 94
Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4925-1 · Cited by 83
NRF2 immunolocalization in human breast cancer patients as a prognostic factor
Onodera, Y., Motohashi, H., Takagi, K., Miki, Y., Shibahara, Y., Watanabe, M., Ishida, T., Hirakawa, H., Sasano, H., Yamamoto, M., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0234 · Cited by 81
Self-citationZhang, G., Wang, Y., Chen, B., Guo, L., Cao, L., Ren, C., Wen, L., Li, K., Jia, M., Li, C., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.23 · Cited by 66
Gloyeske, N. C., Dabbs, D. J., & Bhargava, R. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcp34cysatwfdpq · Cited by 63
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundResting heart rate as a prognostic factor for mortality in patients with breast cancer
Lee, D. H., Park, S., Lim, S. M., Lee, M. K., Giovannucci, E. L., Kim, J. H., Kim, S. I., & Jeon, J. Y. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3938-1 · Cited by 58
Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz135 · Cited by 46
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes
Chun, Y. S., Mizuno, T., Cloyd, J. M., Ha, M. J., Omichi, K., Tzeng, C.-W. D., Aloia, T. A., Ueno, N. T., Kuerer, H. M., Barcenas, C. H., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.214 · Cited by 32
Yap, Y.-S., Leong, M. C., Chua, Y. W., Loh, K. W. J., Lee, G. E., Lim, E. H., Dent, R., Ng, R. C. H., Lim, J. H.-C., Singh, G., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0221305 · Cited by 23
Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiring
Kuzmin, E., Baker, T. M., Lesluyes, T., Monlong, J., Abe, K. T., Coelho, P. P., Schwartz, M., Del Corpo, J., Zou, D., Morin, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113988 · Cited by 20
Kunasegaran, K., Ho, V., Chang, T. H. T., De Silva, D., Bakker, M. L., Christoffels, V. M., & Pietersen, A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110191 · Cited by 18
Qian, X.-L., Xia, X.-Q., Li, Y.-Q., Jia, Y.-M., Sun, Y.-Y., Song, Y.-M., Xue, H.-Q., Hao, Y.-F., Wang, J., Wang, X.-Z., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36517-2 · Cited by 8
Metadata
- Authors
- Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., Hicks, D. G., Lester, S., Love, R., Mangu, P. B., McShane, L., Miller, K., Osborne, C. K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J. N., Sweep, F. C. G., Taube, S., Torlakovic, E. E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R. B., Wittliff, J. L., & Wolff, A. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-06-01
- Volume
- 28
- Issue
- 16
- Pages
- 2784-2795
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137853125
- Cited by
- 4,213
- References
- 59
- FWCI
- 65.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.